Literature DB >> 1618240

The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis.

T S Tracy1, K Krohn, D R Jones, J D Bradley, S D Hall, D C Brater.   

Abstract

We have studied the pharmacokinetics of methotrexate in patients with rheumatoid arthritis concurrently treated with choline magnesium trisalicylate, ibuprofen, naproxen, or a non-NSAID analgesic (control treatment). The apparent systemic clearance of methotrexate was significantly reduced by all three treatments. Trisalicylate and ibuprofen both significantly reduced methotrexate renal clearance, but only the trisalicylate significantly displaced methotrexate from protein, increasing the fraction unbound by 28%. These data show that NSAIDs can affect the disposition of methotrexate, possibly increasing the potential for toxicity and necessitating dosage adjustments. However, large inter-subject variability precludes specific dosage recommendations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618240     DOI: 10.1007/bf00278469

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  Further characterization of specific drug binding sites on human serum albumin.

Authors:  G Sudlow; D J Birkett; D N Wade
Journal:  Mol Pharmacol       Date:  1976-11       Impact factor: 4.436

2.  Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients.

Authors:  R A Herman; P Veng-Pedersen; J Hoffman; R Koehnke; D E Furst
Journal:  J Pharm Sci       Date:  1989-02       Impact factor: 3.534

3.  Methotrexate in rheumatoid arthritis. Health and Public Policy Committee, American College of Physicians.

Authors: 
Journal:  Ann Intern Med       Date:  1987-09       Impact factor: 25.391

4.  The effect of organic acids on renal clearance of methotrexate in man.

Authors:  D G Liegler; E S Henderson; M A Hahn; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

5.  Influence of fraction unbound upon the renal clearance of furosemide in the isolated perfused rat kidney.

Authors:  S Hall; M Rowland
Journal:  J Pharmacol Exp Ther       Date:  1985-01       Impact factor: 4.030

6.  Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve.

Authors:  W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

7.  Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis.

Authors:  K J Skeith; A S Russell; F Jamali; J Coates; H Friedman
Journal:  J Rheumatol       Date:  1990-08       Impact factor: 4.666

8.  Pharmacokinetics of ibuprofen.

Authors:  K S Albert; C M Gernaat
Journal:  Am J Med       Date:  1984-07-13       Impact factor: 4.965

9.  Theoretical analysis of the binding of salicylate by human serum albumin: the relationship between free and bound drug and therapeutic levels.

Authors:  W D Wosilait
Journal:  Eur J Clin Pharmacol       Date:  1976-02-06       Impact factor: 2.953

10.  Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis.

Authors:  S K MacKinnon; G Starkebaum; R F Willkens
Journal:  Semin Arthritis Rheum       Date:  1985-11       Impact factor: 5.532

View more
  18 in total

1.  A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM.

Authors:  F Bressolle; C Bologna; L Edno; J C Bernard; R Gomeni; J Sany; B Combe
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 2.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

3.  Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate.

Authors:  H Franck; R Rau; G Herborn
Journal:  Clin Rheumatol       Date:  1996-03       Impact factor: 2.980

Review 4.  Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.

Authors:  B Bannwarth; F Péhourcq; T Schaeverbeke; J Dehais
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 5.  Drug interactions in childhood cancer.

Authors:  Cyrine Haidar; Sima Jeha
Journal:  Lancet Oncol       Date:  2010-09-22       Impact factor: 41.316

Review 6.  Clinical pharmacokinetics of ibuprofen. The first 30 years.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

7.  The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis.

Authors:  C Godfrey; K Sweeney; K Miller; R Hamilton; J Kremer
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

8.  Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis.

Authors:  T S Tracy; T Worster; J D Bradley; P K Greene; D C Brater
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

9.  Symmetric dimethyl arginine and N-acetyl-β-D-glucosaminidase lysozimuria of proximal renal tubules as a target for nephrotoxicity in patients with rheumatoid arthritis treated with disease modifying antirheumatic drugs.

Authors:  Dejan Spasovski; Arif Latifi; Nada Marina; Jordan Calovski; Irena Kafedziska; Gjorgi Božinovski; Snežana Percinkova; Maja Slaninka-Micevska; Trajan Balkanov; Beti Dejanova; Sonja Alabakovska; Svetlana Krstevska-Balkanov; Goce Spasovski; Dejan Spasovski
Journal:  J Nephropathol       Date:  2013-01-01

Review 10.  Methotrexate in rheumatoid arthritis. An update.

Authors:  B Bannwarth; L Labat; Y Moride; T Schaeverbeke
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.